Double-Drug attack shows promise against tough lung cancer
NCT ID NCT05904379
First seen Mar 13, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study tests two experimental drugs (AK112 and AK104) given together, with or without chemotherapy, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination is safe and helps shrink tumors or slow the disease. About 233 adults aged 18–75 with stage IIIB/C or IV lung cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.